Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
June 4, 2023

Poster HER2-low presented at ASCO2023

Poster HER2-low presented at ASCO2023

Our #ASCO2023 poster on HER2-low was selected for oral presentation by session chair Prof. David Rimm (Yale University School of Medicine). In his discussion he highlighted AI as an essential means to score HER2 in the future. The paper “AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones and scanners” was written together with PD Dr. med. habil. Ramona Erber, Arndt Hartmann, Evgeny / Евгений Dr. Minin / Минин, Hanna Hübner, Carolin Schmidt, Ralf Banisch, Stefan Gunther, Patrick Frey, Tobias Lang, Matthias Ruebner, Peter Andreas Fasching, Niklas Abele, Andreas Mamilos. Thank you to all contributors!

You may also be interested in

March 20, 2024
Meet our experts at USCAP!

We are looking forward to meeting you in person, at USCAP 2024, Baltimore (MD), USA. Meet our CEO Felix Faber and our experts Patrick Frey and Timm Goempel at our booth (no 863).

Read more ⟶
October 10, 2023
Mindpeak sets standards with PD-L1 Cell Atlas

A refined approach for AI-assisted cancer diagnosis was developed by setting standards in the interpretation of scoring guidelines with a "PD-L1 Cell Atlas".

Read more ⟶
August 3, 2023
Diagnostic throughput increased by up to 10x and more patients identified.

In a study investigating the efficiency gain in clinical routine with our AI Unilabs reported saving up to 90% diagnostic time compared to manual scoring. In addition, several patients needed to be re-classified leading to the identification of more patients eligible for treatment in the prospective study setting.

Read more ⟶

Find out more about our AI-based diagnostics

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mindpeak Breast IHC being displayed on a monitor

About Mindpeak

We build automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. Our tools assist cancer experts in providing reliable and reproducible diagnoses.
‍
This frees specialists from tedious, repetitive tasks such as quantification of cells or biomarkers and allows them to focus on tasks where their human expertise is indispensable. Explainable AI (xAI) results provide the required trust of pathologists into our tools.

Company information

Local court Hamburg HRB 151143
‍
Managing director:
Felix Faber
‍
V.A.T. identification number:
DE318495606

Founded in 2018

Contact us

Mindpeak GmbH
Zirkusweg 2
20359 Hamburg
Germany
Email: info@mindpeak.ai
Telephone: +49 40 35 67 67 97

Regulatory Note:
Unless otherwise stated all products are intended for Research Use Only, not for use in diagnostic procedures.

© 2024 Mindpeak GmbH

Supported by:

Horizon 2020 (European Commission)

Privacy policy

Contact